Pharma Companies that Own Covid-19 Vaccines Increase Profits by 59% in 2021

Covid-19, an economic, social, and health setback, but also an economic boost for big pharma companies. Pfizer, Johnson&Johnson (J&J), and AstraZeneca, the three pharmaceutical companies that currently have the green light from the European Medicines Agency (EMA) to inject their vaccines, increased their combined profit by 59.1% in 2021 compared to 2020, according to the latest results published by the different companies and collected by PlantaDoce. This result does not take into account the profit of the biotech companies Moderna and BioNTech, which will present their annual accounts at the end of February and in March, respectively.

The combined profit of J&J, Pfizer, and AstraZeneca reached $48.7 billion (€43 billion) at the end of 2021, compared with $30.6 billion (€27 billion) in 2020. The development of the Covid-19 vaccine and its subsequent approval by the regulatory body have played an important role in the financial performance of these companies. However, AstraZeneca has seen a significant deterioration in its accounts, as its profit plummeted last year.

Pfizer closed 2021 with a profit of $22 billion, compared with $9.16 billion in 2020, according to the latest results published by the U.S. company. The pharma developer of the Covid-19 vaccine Comirnaty recorded a turnover of $81.3 billion in 2021, compared with $41.65 billion achieved a year earlier. The multinational’s biopharmaceuticals division had revenues of $79.55 billion in 2021, up from $40.72 billion in 2020. Within this segment, the vaccines business accounted for sales of $42.62 billion last year, compared with $6.57 billion in 2020.

Read more on the subject and find the latest business headlines in the world with the Born2Invest mobile app.

Pfizer closed 2021 with a profit of $21.98 billion, up from $9.16 billion in 2020

It is not only with vaccines that Pfizer is going strong. Last January, the EMA approved the use of Paxlovid, the U.S. giant’s oral treatment for Covid-19. In December, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the use of Paxlovid for the treatment of mild to moderate Covid-19. Paxlovid is a preparation based on two antivirals, nirmatrelvir, and ritonavir.

Johnson&Johnson, meanwhile, posted a profit of $20.87 billion in 2021, up from $14.71 billion, or 42% more in one year. For the year as a whole, Johnson&Johnson’s turnover was $106.3 billion (€93.77 billion), up 13.6% in 2020. In the next two years, the U.S. multinational will split into two listed companies, splitting its consumer and home health division, which will generate sales of $15 billion this year, according to company forecasts. The multinational will keep its pharmaceutical and medical devices businesses. This move to separate the consumer health division is in line with the context of recent years.

The same cannot be said of AstraZeneca. The Anglo-Saxon drugmaker closed 2021 with a profit of $115 million, down from $3.144 billion in 2020. The company justifies this blow to the accounts due to the acquisition of Alexion, completed during the third quarter of the year for $39 billion, the amortization of intangibles, and impairment and restructuring charges.

Even so, the laboratory’s sales increased by 41% to $37.417 billion. AstraZeneca’s Covid-19 drug Evusheld, which has already earned more than eighty million dollars, began to bear fruit. This treatment will soon reach Spain after the Ministry of Health and the drug company signed a contract a few days ago for the purchase of 30,000 doses. The drug against Covid, Evusheld, has also begun to bear fruit: it has earned $84 million (€74 million). A treatment that will soon reach Spain, after the Ministry of Health and AstraZeneca signed a contract for the purchase of 30,000 doses a few days ago.

__

(Featured image by HakanGERMAN via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.